Sci­ence 37 takes the SPAC short­cut to Nas­daq, land­ing a $235M wind­fall for its push on de­cen­tral­ized tri­als

4 years ago
Deals

With a fresh $75M, Michael Ehler­s' lat­est take on non-vi­ral gene ther­a­py is ready for take­off

4 years ago
Financing

In 'his­toric' pub­lic health step, WHO ful­ly en­dors­es Glax­o­SmithK­line's malar­ia shot

4 years ago
R&D

Tiny play­er picks up $30M to go af­ter CAR-T's biggest chal­lenges

4 years ago
Financing
Startups

ARCH un­veils its Re­al­ly Big Neu­ro­science Com­pa­ny with $500M, an Am­gen deal and eyes on de­pres­sion, Alzheimer's and a ...

4 years ago
Financing
Startups

RA Cap­i­tal kicks off third VC fund as Pe­ter Kolchin­sky and Ra­jeev Shah bank $880M

4 years ago
Financing

FDA+ roundup: Sen. Burr on strength­en­ing FDA's readi­ness; ICH guide­line adop­tion; Long­time FDA lawyer re­tires and ...

4 years ago
FDA+

Two decades af­ter dis­cov­er­ing a new way to con­struct mol­e­cules, David MacMil­lan and Ben­jamin List win No­bel Prize

4 years ago
People

Ae­tion to col­lab­o­rate with UK's NICE on RWE; 4D's cys­tic fi­bro­sis gene ther­a­py cleared for clin­i­cal tri­als

4 years ago
News Briefing

UBS wants to make an 'im­pact' with a new fund, shelling out $650M to join MPM

4 years ago
Financing

Break­ing: Pfiz­er de­vel­op­ment chief Rod MacKen­zie is re­tir­ing af­ter a lengthy ca­reer capped by his­toric suc­cess

4 years ago
People

A short-sell at­tack sends Ginkgo's share price spin­ning, un­der­scor­ing in­vestors' con­cerns over syn­bio field

4 years ago
Pharma

FDA of­fers sup­port for Takeda's po­ten­tial cy­tomegalovirus drug ahead of ad­comm

4 years ago
Pharma
FDA+

Is the biotech boom start­ing to fade? The roar­ing ‘20s starts to look a lit­tle fa­tigued. Plus: Top 5 deals, IPOs, ...

4 years ago
Deals
Bioregnum

Take­da flash­es red light on 'break­through' nar­colep­sy drug af­ter PhII tri­als turned up mys­te­ri­ous safe­ty sig­nal

4 years ago
R&D

Covid-19 roundup: Sin­ga­pore and South Ko­rea are the lat­est to ink sup­ply deals for break­through Covid-19 pill

4 years ago
Coronavirus

An ul­tra-rare dis­ease drug missed on func­tion but hit on sur­vival and mor­tal­i­ty. Is it enough for the FDA?

4 years ago
R&D

NFX tar­gets seed and pre-seed com­pa­nies with lat­est $450M round

4 years ago
Financing

Trou­bled Voy­ager’s gene ther­a­py re­launch gets a boost with $630M Pfiz­er deal

4 years ago
Deals
Cell/Gene Tx

Un­fazed by OS flop, Zai Lab eyes im­mi­nent Chi­na fil­ing for Macro­Gen­ic­s' HER2 drug

4 years ago
R&D
China

FDA cen­ter di­rec­tors on lessons from the EUA path­way: Flex­i­bil­i­ty serves us well

4 years ago
FDA+
Coronavirus

Af­ter a brief stint in the top can­cer re­search spot at Gilead, Va­le­ria Fan­tin jumps over to Sanofi

4 years ago
People
Pharma

Ex-FDA of­fi­cials ask SCO­TUS to take up J&J talc case; An­no­vis shows da­ta from PhII Parkin­son's tri­al

4 years ago
News Briefing

Medicxi co-founder David Grainger gets his oth­er foot in Centes­sa's door as chief in­no­va­tion of­fi­cer

4 years ago
People
First page Previous page 640641642643644645646 Next page Last page
A service from the Financial Times